SILVERBOX CORP IV

Item 7.01 Regulation FD Disclosure. As previously announced on June 9, 2025, SilverBox Corp IV (“SBXD”) and Parataxis Holdings LLC (“Parataxis Holdings”) entered into a non-binding letter of intent for a potential business combination. On June 20, 2025, Parataxis Holdings issued a press release announcing a definitive agreement to acquire a controlling interest in Bridge Biotherapeutics, Inc., a Korean company listed on the KOSDAQ. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. In addition, the following is a LinkedIn post by Joseph E. Reece, Founder Partner of SBXD: Parataxis Holdings announces definitive agreement to establish a Bitcoin treasury company in South Korea Read the press release of Parataxis Holdings here: Parataxis Holdings LLC Announces Definitive Agreement with Bridge Biotherapeutics, Inc. (KOSDAQ: 288330), to Bring Institutionally-Backed, Bitcoin Treasury Company to the South Korean Public Markets. The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the filings of SBXD under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.